Qlaris Bio is developing a novel fixed-dose combination (FDC) therapy that combines its investigational drug QLS-111 with latanoprost for the treatment of glaucoma, the company recently reported. The preservative-free formulation, QLS-111-FDC, is being designed for patients with primary open-angle glaucoma, ocular hypertension, and normal-tension glaucoma who may require enhanced intraocular pressure (IOP) control, according to a press release.

QLS-111 is a first-in-class topical ATP-sensitive potassium channel modulator developed to lower IOP by reducing episcleral venous pressure (EVP), a component of IOP not targeted by currently approved therapies. Latanoprost, a widely used prostaglandin analogue, reduces IOP by increasing uveoscleral outflow. The combination is expected to provide a synergistic dual mechanism for more effective IOP control.

When added to latanoprost monotherapy in the Apteryx phase 2 study, QLS-111 reduced IOP by over 3 mmHg more than latanoprost alone. This additive benefit occurred without increased hyperemia or other clinically significant adverse events.

A fixed-dose combination could simplify treatment regimens for patients who struggle with multiple medications and could improve adherence and outcomes, the company said. The combination represents a new direction in glaucoma therapy by addressing EVP and distal outflow resistance together. GP